Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
CPIX Cumberland Pharmaceuticals Inc
- Stocks
- Healthcare
- NASDAQ: CPIX
Price (delayed)
$4.71
Market cap
$70.47M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.25
Enterprise value
$65.8M
Cumberland Emerging Technologies, Inc.(www.cet-fund.com)is a joint initiative between Cumberland Pharmaceuticals Inc., Vanderbilt University, LaunchTN and WinHealth Pharma. The mission of CET is to bring biomedical technologies and products conceived at
Highlights
The net income has soared by 61% YoY and by 49% QoQ
Cumberland Pharmaceuticals's EPS has soared by 58% YoY and by 46% from the previous quarter
The quick ratio has decreased by 9% YoY but it has increased by 6% QoQ
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.cumberlandpharma.com
Key stats
What are the main financial stats of CPIX
Market
Valuations
Earnings
Shares outstanding
14.96M
Market cap
$70.47M
Enterprise value
$65.8M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.3
Price to sales (P/S)
1.71
EV/EBIT
N/A
EV/EBITDA
20.12
EV/Sales
1.6
Revenue
$41.08M
Gross profit
$34.65M
Operating income
-$3.27M
Net income
-$3.28M
EBIT
-$2.65M
EBITDA
$3.27M
Free cash flow
$4.07M
Per share
Balance sheet
Liquidity
EPS
-$0.25
EPS diluted
-$0.25
Free cash flow per share
$0.27
Book value per share
$2.05
Revenue per share
$2.75
TBVPS
$3.48
Total assets
$69.94M
Total liabilities
$41.6M
Debt
$10.44M
Equity
$28.66M
Working capital
$6.36M
Debt to equity
0.36
Current ratio
1.25
Quick ratio
1
Net debt/EBITDA
-1.43
Margins
Efficiency
Dividend
EBITDA margin
8%
Gross margin
84.3%
Net margin
-8%
Operating margin
-8%
Return on assets
-4.4%
Return on equity
-12.8%
Return on invested capital
-9.2%
Return on capital employed
-6%
Return on sales
-6.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CPIX stock price
How has the Cumberland Pharmaceuticals stock price performed over time
Intraday
-10.11%
1 week
0.21%
1 month
3.97%
1 year
214%
YTD
98.73%
QTD
11.35%
Financial performance
How have Cumberland Pharmaceuticals's revenue and profit performed over time
Revenue
$41.08M
Gross profit
$34.65M
Operating income
-$3.27M
Net income
-$3.28M
Gross margin
84.3%
Net margin
-8%
The company's operating margin has surged by 69% YoY and by 53% QoQ
CPIX's operating income has surged by 67% year-on-year and by 49% since the previous quarter
The company's net margin has surged by 63% YoY and by 53% QoQ
The net income has soared by 61% YoY and by 49% QoQ
Price vs fundamentals
How does CPIX's price correlate with its fundamentals
Growth
What is Cumberland Pharmaceuticals's growth rate over time
Valuation
What is Cumberland Pharmaceuticals stock price valuation
P/E
N/A
P/B
2.3
P/S
1.71
EV/EBIT
N/A
EV/EBITDA
20.12
EV/Sales
1.6
Cumberland Pharmaceuticals's EPS has soared by 58% YoY and by 46% from the previous quarter
CPIX's P/B is 130% above its 5-year quarterly average of 1.0 and 77% above its last 4 quarters average of 1.3
CPIX's equity is up by 25% since the previous quarter and by 4.2% year-on-year
The stock's price to sales (P/S) is 90% more than its last 4 quarters average of 0.9 and 71% more than its 5-year quarterly average of 1.0
The revenue has grown by 8% from the previous quarter and by 6% YoY
Efficiency
How efficient is Cumberland Pharmaceuticals business performance
Cumberland Pharmaceuticals's ROS has soared by 68% YoY and by 58% from the previous quarter
CPIX's return on invested capital has surged by 61% year-on-year and by 49% since the previous quarter
The ROA has soared by 56% YoY and by 47% from the previous quarter
The company's return on equity has surged by 51% YoY and by 50% QoQ
Dividends
What is CPIX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CPIX.
Financial health
How did Cumberland Pharmaceuticals financials performed over time
The total assets is 68% greater than the total liabilities
The company's total liabilities fell by 23% YoY and by 22% QoQ
The total assets has declined by 14% year-on-year and by 7% since the previous quarter
The company's debt is 64% lower than its equity
The debt to equity has plunged by 60% from the previous quarter and by 54% YoY
The company's debt has shrunk by 52% YoY and by 49% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.